Acticor taps Merck's MilliporeSigma for manufacturing services

The German company's US business ties up a manufacturing deal with a French biotech.

By Suzanne Elvidge • Dec. 8, 2016

Sanofi taps JHL for access to biosimilars in China

The French pharma hopes to gain access to the growing pharmaceutical market in China through the deal. 

By Suzanne Elvidge • Dec. 7, 2016

Spark teams up with Selecta on gene therapies

The gene therapy biotech will use Selecta's technology platform to bolster the efficacy of its hemophilia therapies. 

By Lisa LaMotta • Dec. 5, 2016

Acetylon forms Regenacy ahead of Celgene takeover

Boston biotech Acetylon revealed it was being acquired by Celgene and rolled out a new business to continue production of gene expression drugs. 

By Jacob Bell • Dec. 5, 2016

Prescribed Reading: Spotlight on CAR-T, Cures

AstraZeneca inks small deal that will fit into its new focus; the upcoming ASH meeting will highlight the progress in CAR-T; and the Cures Act gets support from the industry. 

By Lisa LaMotta • Dec. 2, 2016

Roche brings Kapa into partnership with German Merck

The Swiss biopharma has expanded two distribution deals this week, one for its own enzyme products and one for another drugmaker's diabetes technology.

By Jacob Bell • Dec. 2, 2016

Little meets large: Bicycle inks deal with AstraZeneca

The small UK biotech believes its peptide technology combines the targeting specificity of antibodies with the dosing flexibility of small molecules. 

By Suzanne Elvidge • Dec. 2, 2016

Sangamo to transfer two gene therapies to Biogen spin-off

Adding the hemoglobinopathy programs, which Sangamo had partnered with Biogen on, will bolster the fledgling Bioverativ's pipeline in rare blood disorders. 

By Judy Packer-Tursman • Dec. 1, 2016

Patheon snaps up SC manufacturing site from Roche

The Swiss pharma has been trimming its small molecule manufacturing network, tagging four plants worldwide for sale. 

By Judy Packer-Tursman • Nov. 30, 2016

Oxford BioMedica and Orchard ink gene therapy deal

Strategic alliance combines gene and cell therapy approaches for rare immune diseases.

By Suzanne Elvidge • Nov. 30, 2016

MedImmune, Abpro link up to accelerate antibody development

The deal adds to what has been a hectic few months of M&A for AstraZeneca, MedImmune's parent company. 

By Jacob Bell • Nov. 29, 2016

Idera sells licensing rights to shelved autoimmune drug

The deal gives Idera, which has been hungry for cash to push candidates through clinical trials, $15 million upfront. 

By Jacob Bell • Nov. 28, 2016

J&J gives nod to Actelion rumors

Companies confirmed talks for a deal that could be worth more than $20 billion.

By Suzanne Elvidge • Nov. 28, 2016

Allergan builds Alzheimer's portfolio with Chase acquisition

The deal came just hours before Eli Lilly announced its highly anticipated Alzheimer's treatment failed in Phase 3. 

By Jacob Bell • Nov. 23, 2016

Quintiles IMS hooks up with big pharma on data deal

Collaboration with the pharma industry will give QuintilesIMS access to real-world cancer data.

By Suzanne Elvidge • Nov. 23, 2016

Walgreens expands partnership providing patient drug reviews

The deal will provide more detailed product reviews from online forum PatientLikeMe's more than 400,000 users.

By Jacob Bell • Nov. 22, 2016

Novartis snags sickle cell drug in Selexys acquisition

The deal, worth up to $665 million, further solidifies the Swiss pharma's footing in the hematology drug space.

By Jacob Bell • Nov. 21, 2016

Prescribed Reading: Data, arrests, pricing batter pharma

Gilead falters, ex-Valeant exec indicted, combo data dominates in hep C and pricing worries continue. 

By Lisa LaMotta • Nov. 18, 2016

GlobeImmune CEO steps down as partnership with Gilead fizzles

The announcements continue a string of bad news that has plagued the clinical-stage biopharma for more than a year.

By Jacob Bell • Nov. 18, 2016

Grunenthal buys Pittsburgh firm to expand pain-fighting portfolio

Thar Pharmaceuticals abandons IPO plans in favor of deal with German giant.

By Judy Packer-Tursman • Nov. 18, 2016

Eagle acquires Arsia, moves in on biosimilars

The target company's technology platform will allow Eagle to soar above other biosimilar developers.

By Jacob Bell • Nov. 17, 2016

Bristol continues microbiome exploration with Enterome deal

The agreement follows Bristol's decision earlier this month to partner with Johns Hopkins University on research into the hot field. 

By Jacob Bell • Nov. 16, 2016

Prescribed Reading: Trump wasn't the only news in pharma

Bristol-Myers made portfolio changes, Europe welcomed several biosimilars to market, the FDA talked off-label promotion and multiple drugs were hit with holds. 

By Lisa LaMotta • Nov. 11, 2016

Bristol digs deeper into NASH with Nitto deal

Like other pharmas, Bristol-Myers sees potential in the unmet need for treatments of the fatty liver disease. 

By Jacob Bell • Nov. 10, 2016

Orexigen and Valeant bulk up Contrave deal

The two floundering companies expanded a marketing partnership into new territories. 

By Lisa LaMotta • Nov. 9, 2016